KLP Kapitalforvaltning AS Acquires New Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

KLP Kapitalforvaltning AS acquired a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 16,600 shares of the company’s stock, valued at approximately $219,000.

A number of other large investors also recently bought and sold shares of the company. R Squared Ltd acquired a new position in shares of Syndax Pharmaceuticals during the fourth quarter worth about $26,000. Cape Investment Advisory Inc.



boosted its holdings in Syndax Pharmaceuticals by 157.1% in the 4th quarter. Cape Investment Advisory Inc.

now owns 6,427 shares of the company’s stock valued at $85,000 after purchasing an additional 3,927 shares in the last quarter. KBC Group NV boosted its holdings in Syndax Pharmaceuticals by 104.8% in the 4th quarter.

KBC Group NV now owns 6,954 shares of the company’s stock valued at $92,000 after purchasing an additional 3,559 shares in the last quarter. E Fund Management Co. Ltd.

increased its position in Syndax Pharmaceuticals by 14.4% during the 4th quarter. E Fund Management Co.

Ltd. now owns 12,603 shares of the company’s stock worth $167,000 after purchasing an additional 1,583 shares during the period. Finally, China Universal Asset Management Co.

Ltd. raised its stake in shares of Syndax Pharmaceuticals by 10.6% during the 4th quarter.

China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company’s stock worth $239,000 after buying an additional 1,732 shares in the last quarter.

Syndax Pharmaceuticals Trading Down 2.1 %NASDAQ:SNDX opened at $11.01 on Tuesday.

The company has a market capitalization of $947.34 million, a P/E ratio of -3.03 and a beta of 1.

28. The firm has a 50-day moving average price of $14.06 and a two-hundred day moving average price of $15.

60. Syndax Pharmaceuticals, Inc. has a twelve month low of $10.

14 and a twelve month high of $25.07. Syndax Pharmaceuticals (NASDAQ:SNDX – Get Free Report) last issued its quarterly earnings data on Monday, March 3rd.

The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.

79). The firm had revenue of $7.68 million for the quarter, compared to analyst estimates of $86.

32 million. On average, equities research analysts predict that Syndax Pharmaceuticals, Inc. will post -3.

72 earnings per share for the current year. Analysts Set New Price TargetsA number of analysts recently weighed in on the company. StockNews.

com upgraded Syndax Pharmaceuticals to a “sell” rating in a research note on Wednesday, April 2nd. JPMorgan Chase & Co. boosted their target price on shares of Syndax Pharmaceuticals from $39.

00 to $41.00 and gave the stock an “overweight” rating in a research report on Thursday, March 20th. Scotiabank lowered their price target on shares of Syndax Pharmaceuticals from $18.

00 to $16.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. Citigroup reduced their price objective on shares of Syndax Pharmaceuticals from $45.

00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Finally, HC Wainwright restated a “buy” rating and set a $51.

00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $36.

20.Check Out Our Latest Stock Analysis on Syndax PharmaceuticalsInsiders Place Their BetsIn related news, CFO Keith A. Goldan sold 3,777 shares of the business’s stock in a transaction dated Monday, February 10th.

The shares were sold at an average price of $15.50, for a total value of $58,543.50.

Following the completion of the transaction, the chief financial officer now owns 90,746 shares of the company’s stock, valued at approximately $1,406,563. The trade was a 4.00 % decrease in their position.

The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Metzger sold 13,288 shares of the firm’s stock in a transaction dated Monday, February 10th.

The stock was sold at an average price of $15.50, for a total transaction of $205,964.00.

Following the sale, the chief executive officer now directly owns 300,121 shares in the company, valued at $4,651,875.50. This represents a 4.

24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 21,683 shares of company stock valued at $336,087.

Corporate insiders own 4.10% of the company’s stock. Syndax Pharmaceuticals Profile (Free Report)Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.

Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).See AlsoFive stocks we like better than Syndax PharmaceuticalsFollowing Congress Stock TradesOptions Activity Points to More Volatility for Palantir StockMarket Cap Calculator: How to Calculate Market CapNVIDIA Stock: Oversold, Undervalued — How Low Can It Go?Diversification Can Smooth Returns And Mitigate Portfolio RiskMicroStrategy Sees Insider Buy-Sell Action in Q1.